<DOC>
	<DOC>NCT01828957</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk premature infants by comparing Pneumostem-treated group with a control group.</brief_summary>
	<brief_title>Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<criteria>Age: 5 14 days since birth Fetal gestational age: ≥23 weeks and &lt;29 weeks Birth weight: ≥500g and ≤1250g Premature infant of equal to or less than 2 weeks of age who is receiving a ventilator therapy at a rate of &gt; 12 breath/min and &gt; 25% oxygen Patient whose ventilator setting has not been changed and who has shown aggravation of the illness within the 24 hours prior to the study enrollment Patient with a written consent form signed by a legal representative or a parent upon explanation of the clinical trial Patient with concurrent cyanotic or acyanotic congenital heart diseases, except for patent ductus arteriosus Patient with a concurrent severe lung malformation (i.e. Pulmonary hypoplasia, congenital diaphragmatic hernia, congenital cystic lung disease) Patient with a concurrent severe lung malformation with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc) Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc) Patient withCRP &gt; 30 mg/dL; Severe sepsis or shock Patient who is scheduled for or expected to undergo a surgical procedure 72 hours prior to/following the administration of the study drug Patient who has been administered with a surfactant within the 24 hours prior to the administration of the study drug Patient with severe intracranial hemorrhage ≥ grade 3 or 4 Patient with active pulmonary hemorrhage or active air leak syndrome at the time of screening Patient with a history of participating in other clinical studies Patient who is allergic to Gentamicin Patient who is considered inappropriate to participate in the study by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Days</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Human Umbilical Cord Blood Derived Mesenchymal Stem Cells</keyword>
	<keyword>Bronchopulmonary dysplasia</keyword>
	<keyword>Premature infants</keyword>
</DOC>